BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24296834)

  • 21. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
    Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
    J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Landscape of circulating tumour DNA in metastatic breast cancer.
    Davis AA; Jacob S; Gerratana L; Shah AN; Wehbe F; Katam N; Zhang Q; Flaum L; Siziopikou KP; Platanias LC; Gradishar WJ; Behdad A; Cristofanilli M
    EBioMedicine; 2020 Aug; 58():102914. PubMed ID: 32707446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of Activating Estrogen Receptor Gene (
    Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
    Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
    [No Abstract]   [Full Text] [Related]  

  • 29. Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
    Cao W; Xu Y; Chang L; Gong Y; Li L; Mo X; Zhang X; Lin G; Zhou J; Liu D; Yi Y; Dai P; Zhu C; Liu T; Chu Y; Guan Y; Chen Y; Wang J; Xia X; Yang L; Yi X; Cheng Y
    Mol Cancer Ther; 2019 Jun; 18(6):1158-1167. PubMed ID: 31015309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect rare mutations in circulating tumor DNA.
    Ahn J; Hwang B; Young Kim H; Jang H; Kim HP; Han SW; Kim TY; Hyun Lee J; Bang D
    Sci Rep; 2017 May; 7():46678. PubMed ID: 28462938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of a Targeted Sequencing Assay to Detect Rare Mutations in Circulating Tumor DNA.
    Chen J; Chen J; He F; Huang Y; Lu S; Fan H; Wang M; Xu R
    Genet Test Mol Biomarkers; 2019 Apr; 23(4):264-269. PubMed ID: 30986100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang Z; Cheng Y; An T; Gao H; Wang K; Zhou Q; Hu Y; Song Y; Ding C; Peng F; Liang L; Hu Y; Huang C; Zhou C; Shi Y; Zhang L; Ye X; Zhang M; Chuai S; Zhu G; Hu J; Wu YL; Wang J
    Lancet Respir Med; 2018 Sep; 6(9):681-690. PubMed ID: 30017884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy and reproducibility of somatic point mutation calling in clinical-type targeted sequencing data.
    Karimnezhad A; Palidwor GA; Thavorn K; Stewart DJ; Campbell PA; Lo B; Perkins TJ
    BMC Med Genomics; 2020 Oct; 13(1):156. PubMed ID: 33059707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients.
    Sun MY; Lin FQ; Chen LJ; Li H; Lin WQ; Du HY; Yang XX; Li M
    Curr Oncol; 2021 Jun; 28(4):2326-2336. PubMed ID: 34202466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Technical progress in circulating tumor DNA analysis using next generation sequencing.
    Bai Y; Wang Z; Liu Z; Liang G; Gu W; Ge Q
    Mol Cell Probes; 2020 Feb; 49():101480. PubMed ID: 31711827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
    Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
    Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
    Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
    Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.
    Bratman SV; Newman AM; Alizadeh AA; Diehn M
    Expert Rev Mol Diagn; 2015 Jun; 15(6):715-9. PubMed ID: 25773944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.